Degradation of p53 by human Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Fu, Leiping ^a,c   van Doorslaer, Koenraad ^a   Chen, Zigui ^a   Ristriani, Tutik ^b   Masson, Murielle ^b   Travé, Gilles ^b   Burk, Robert D ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CNRS   (France)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; PROTEIN E6; PROTEIN P53; ONCOPROTEIN;

ALPHAPAPILLOMAVIRUS; ARTICLE; CARCINOGENICITY; CLADISTICS; CONTROLLED STUDY; CORRELATION FUNCTION; EMBRYO; GENETIC CORRELATION; HUMAN; HUMAN CELL; MOLECULAR PHYLOGENY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; POPULATION RESEARCH; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; SPECIES DIFFERENCE; UTERINE CERVIX CANCER; VIRUS STRAIN; AMINO ACID SEQUENCE; CELL LINE; CHEMISTRY; CLASSIFICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; PAPILLOMAVIRUS INFECTION; PHYLOGENY; UTERINE CERVIX TUMOR; VIROLOGY;

ALPHAPAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS;

ALPHAPAPILLOMAVIRUS; AMINO ACID SEQUENCE; CELL LINE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PHYLOGENY; SEQUENCE ALIGNMENT; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS;

EID: 77958565429     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012816     Document Type: Article

References (36)

1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324: 17-27.
2. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, et al. (2010) Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79.
3. zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384: 260-265.
4. Parkin DM, Bray F (2006) Chapter 2: The burden of HPV-related cancers. Vaccine 24(Suppl 3): S11-25.
5. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, et al. (2007) Human papillomavirus type distribution in invasive cervical cancer and highgrade cervical lesions: a meta-analysis update. Int J Cancer 121: 621-632.
6. Hebner CM, Laimins LA (2006) Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 16: 83-97.
7. McLaughlin-Drubin ME, Munger K (2009) Oncogenic activities of human papillomaviruses. Virus Res 143: 195-208.
8. Howie HL, Katzenellenbogen RA, Galloway DA (2009) Papillomavirus E6 proteins. Virology 384: 324-334.
9. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
10. Menendez D, Inga A, Resnick MA (2009) The expanding universe of p53 targets. Nat Rev Cancer 9: 724-737.
11. Brosh R, Rotter V (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713.
12. Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431.
13. Lechner MS, Laimins LA (1994) Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68: 4262-4273.
14. Mantovani F, Banks L (2001) The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20: 7874-7887.
15. Chen Z, Terai M, Fu L, Herrero R, DeSalle R, et al. (2005) Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J Virol 79: 7014-7023.
16. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R (2000) Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 19: 5270-5280.
17. Auersperg N (1964) Long-Term Cultivation of Hypodiploid Human Tumor Cells. J Natl Cancer Inst 32: 135-163.
18. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, Howley PM (1985) Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 119: 361-366.
19. Graham FL, van der Eb AJ (1973) A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456-467.
20. Chen Z, Fu L, Herrero R, Schiffman M, Burk RD (2007) Identification of a novel human papillomavirus (HPV97) related to HPV18 and HPV45. Int J Cancer 121: 2947-2952.
21. Nomine Y, Masson M, Charbonnier S, Zanier K, Ristriani T, et al. (2006) Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21: 665-678.
22. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136.
23. Schiffman M, Clifford G, Buonaguro FM (2009) Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 4: 8.
24. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. (2009) A review of human carcinogens-Part B: biological agents. Lancet Oncol 10: 321-322.
25. Liu Y, Chen JJ, Gao Q, Dalal S, Hong Y, et al. (1999) Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 73: 7297-7307.
26. Pim D, Banks L (1999) HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 18: 7403-7408.
27. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM (2010) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer.
28. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, et al. (2005) The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337: 76-84.
29. Hiller T, Poppelreuther S, Stubenrauch F, Iftner T (2006) Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Cancer Epidemiol Biomarkers Prev 15: 1262-1267.
30. Berkhout RJ, Bouwes Bavinck JN, ter Schegget J (2000) Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J Clin Microbiol 38: 2087-2096.
31. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, et al. (2000) Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 61: 289-297.
32. Pfister H (2003) Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr. pp 52-56.
33. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63: 4417-4421.
34. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, et al. (2005) Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191: 1796-1807.
35. Narechania A, Chen Z, DeSalle R, Burk RD (2005) Phylogenetic incongruence among oncogenic genital alpha human papillomaviruses. J Virol 79: 15503-15510.
36. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.